Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Most ureteral stent insertions follow ureteroscopy procedures for stone management. Stents
are essentially designed to prevent the blockage of the ureter. Such blockage is often a
result of inflammation caused by ureteroscopy procedures. The stent provides a secure
passageway for urine as it travels from the kidneys to the bladder, circumventing potential
urinary retention. In our community, only one kind of stent is used, and it is manufactured
by Bard. Standard protocol involves the removal of the stent 5 to 8 days following insertion.
If stenting is required for greater than 8 days, special accommodations will be made for you
in this study.
Unfortunately, pain and lower urinary tract symptoms are often associated with the insertion
and removal of stents. It is our goal to determine whether VESIcare is capable of relieving
such symptoms.
As a prospective member of this study, you will be asked to complete three surveys. The first
survey will ask you about your experiences of urinary urgency and pain before your surgery.
If you are an emergency patient, you will be asked to remember your condition before the
surgery, completing this questionnaire at your first post-op visit. If you are not an
emergency patient, this survey will be completed before your surgery. If your stent is
removed within 5 to 8 days of surgery, you will be asked to complete the second survey at the
time of removal. You will then complete the final survey at a scheduled post-operative
check-up 4 to 5 weeks later. If your stent remains inserted for greater than 8 days after
surgery, you will be asked to complete the second survey 3 to 4 days after your stent was
inserted. You will then complete the final survey, 7 to 8 weeks post-op.
Throughout this study, both VESIcare and non-VESIcare patients will be important in
determining whether VESIcare truly is capable of relieving stent pain. As such, you will be
randomly assigned to one of the two groups, those receiving VESIcare, and those who are not.